Sagimet Biosciences (SGMT) Earnings Date & Reports

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SGMT is expected to report earnings to rise 224.24% to -107 cents per share on August 19

Sagimet Biosciences SGMT Stock Earnings Reports

Q2'26

Est.

$-1.07

Q1'26

Beat

by $0.69

Q4'25

Beat

by $0.91

Q3'25

Beat

by $0.64

Q2'25

Beat

by $0.56

The last earnings report on May 12 showed earnings per share of -33 cents, beating the estimate of -101 cents. With 293.48K shares outstanding, the current market capitalization sits at 444.00M.

View a ticker or compare two or three

Compare

SGMT

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for SGMT